← Leaderboards
John Mullinax
H. Lee Moffitt Cancer Ctr & Res Inst
$1,226,480
Attributed
$1,226,480
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $245.3K · FY2020–24$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,226,480 · 1
By mechanism
K08$1,226,480 · 1
Top collaborators
No co-investigators on record.
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Gary Martinez$1,345,227
- Robert Gillies$882,058
- Hatem Soliman$1,291,495
- Nikhil Khushalani$898,592
- Jose R Conejo-Garcia$21,497,732
Others in their field
Other Emerging Leaders on “Clonal Expansion”
- Priyamvada Acharya · Duke University$20,941,151
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$14,031,836
- Sara Gianella Weibel · University Of California, San Diego$8,231,810
- Sandhya Vasan · Henry M. Jackson Fdn For The Adv Mil/Med$7,776,394
- Pradeep Natarajan · Massachusetts General Hospital$4,533,362
- Alexander Bick · Vanderbilt University Medical Center$4,117,054
Research focus
Clonal ExpansionAdvisory CommitteesAdoptive Cell TransfersClinical Trials DesignAutologousAwardAge GroupBioinformaticsBiometryAdaptive Immune ResponseCareerCareer DevelopmentCd8-Positive T-LymphocytesCellsCellular ImmunotherapyCervicalCessation Of LifeChildhoodChromosomal TranslocationClinical PracticeCancer CenterAntitumor ResponseClinical TrialsCoculture Techniques
Grant awards (5)
Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy$245,296
K08 · FY2024 · CA · contact PI
Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy$245,296
K08 · FY2023 · CA · contact PI
Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy$245,296
K08 · FY2022 · CA · contact PI
Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy$245,296
K08 · FY2021 · CA · contact PI
Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy$245,296
K08 · FY2020 · CA · contact PI